Chief Scientific Officer
Michael Agrez MBBS MS PhD FRCS FRACS
Michael’s career background is a combination of basic science research and clinical practice as a colorectal surgeon that commenced while at the Mayo Clinic. Subsequently, during his 30-year tenure with The University of Newcastle, Australia, he has published numerous articles in peer-reviewed journals that cover aspects of epidemiology, cancer screening, molecular biology, biochemistry and immunology. During the past 10 years InterK has developed immuno-modulating peptides that have potential to inhibit cancer growth, autoimmune responses, endometriosis, and radiation-induced DNA damage.
A/g CEO
Stephen Parker, Business Operations
Stephen has worked across biotechnology product development and commercialisation for more than 35 years. Prior to joining InterK, he patented and successfully commercialised a range of surgical devices. He has broad experience in business operations, product development, and strategic coordination relevant to the advancement of InterK’s peptide therapeutics program. He holds a Bachelor of Arts from the University of Sydney, with studies in Government and International Relations, and in Japanese studies.
Share this page